HAYWARD, Calif.--Metabolex, a privately held development-stage pharmaceutical company here, announced its second collaboration agreement with Warner-Lambert in diabetes research. The new deal is a five-year collaboration that will use genomics to discover and develop new therapeutics that treat type-2 diabetes by counteracting insulin resistance. Payments to Metabolex prior to commercialization could exceed $50 million. Further financial terms of the agreement were not disclosed.
Metabolex, Warner-Lambert In $50 M Diabetes Deal
Jun 07, 2000